The medicine price methodology and the clawback tax paid by drug producers are the main obstacle on the Romanian pharmaceutical market and the risk patients are subject to comes from a lack of drugs on the market, said Christian Rodseth, managing director Janssen, pharmaceutical companies of Johnson & Johnson.
Speaking at ZF Pharma Summit 2017 conference on Wednesday, Rodseth said the medicine pricing methodology in Romania makes no sense, adding Romania has the lowest drug prices in the region, but medicines are not available across the country.
According to Rodseth, people might not have access to medicines and a free price is a solution to make sure a certain medicine does not leave the country before it reaches patients.
Cost-volume agreements must be extended on a longer period.